Nuvilex has contracted with Inno Biologics to generate cell clones that will be the basis of the Nuvilex's future Phase III cancer clinical trials. Financial and other terms of the pact were not disclosed.
From Inno's clones, those with the highest enzyme activity that activates the cancer drug ifosfamide will be advanced through further testing. Eventually the best cell clones will be propagated and one will be prepared for encapsulation as part of the Company's treatment for advanced, inoperable pancreatic cancer as well as used to develop future treatments for other cancers.
Inno Biologics, a partner of Boehringer Ingelheim, has cGMP facilities that have been constructed to comply with regulations of both FDA and EMA. Inno Biologics is in close geographic proximity to the storage facilities of Fisher BioServices in Singapore and to Austrianova Singapore.
Dr. Robert F. Ryan, Nuvilex's president and chief executive officer, commented, "It is important to note we have selected an FDA-recognized and cGMP-compliant company to carry out the critical cell cloning portion of our overall developmental plan. Nuvilex will continue to employ the most stringent and prudent criteria in selecting entities to assist us in preparing for our future clinical trials."